NANO Nordic Nanovector ASA

Nordic Nanovector ASA: Mandatory Notification of Trade - Primary Insiders

OSLO, Norway--(BUSINESS WIRE)--

On 9 December 2016, Ludvik Sandnes, who is the chairman of the board of directors Nordic Nanovector ASA (the "Company") (OSE:NANO) (OSE:NANOO) purchased 1000 shares in the Company at an average price of NOK 115.00 per share. Following this transaction, Ludvik Sandnes owns 126,000 shares in the Company and holds 21,604 restricted stock units in the Company. This information is subject to duty of disclosure pursuant to Section 4-2 of the Norwegian Securities Trading Act

This information was brought to you by Cision http://news.cision.com

EN
09/12/2016

Underlying

NANONordic Nanovector ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nordic Nanovector ASA

Patrik Ling
  • Patrik Ling
Free Trial
NANO Nordic Nanovect...

Nordic Nanovector (No_rec, TP: NOK) - Discontinuing coverage

We have discontinued coverage of Nordic Nanovector due to a reallocation of analyst resources. Our last published recommendation, target price and estimates should no longer be relied upon.

NANO NORDIC NANOVECTOR ASA
02/13/23 February 13, 2023 1 EN
Patrik Ling
  • Patrik Ling
Free Trial
NANO Nordic Nanovect...

Nordic Nanovector (No_rec, TP: NOK) - Proposed merger with APIM Therap...

Nordic Nanovector has concluded its strategic review, and the outcome is a proposed merger with the unlisted Norwegian company APIM Therapeutics. Under the proposed terms of the merger, the owners of APIM Therapeutics are set to have c76% of the combined entity, while Nordic Nanovector’s owners would have c24%. An EGM has been scheduled for 1 December or thereabouts and, if approved, the transaction should close in late Q4. We have removed our recommendation and target price following the strate...

NANO NORDIC NANOVECTOR ASA
11/14/22 November 14, 2022 1 EN
Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Artiach
NANO Nordic Nanovect...

Nordic Nanovector - Terminating coverage

ABGSC ceases coverage of Nordic Nanovector SELL is our final recommendation NOK 1.5 is our final target price

NANO NORDIC NANOVECTOR ASA
10/10/22 October 10, 2022 1 EN
Patrik Ling
  • Patrik Ling
Free Trial
NANO Nordic Nanovect...

Nordic Nanovector (Hold, TP: NOK1.60) - Limited visibility on strategi...

The decision to terminate the PARADIGME phase IIb trial in Q2 clearly has major repercussions for Nordic Nanovector given it was the most mature development project in its pipeline. Operations have already been drastically downsized, with c70% of personnel laid off. No new data or real explanation for the weak efficacy in the trial was given, and with limited value in the early-stage pipeline in our view, we value the company at its end-2022e cash position. We reiterate our HOLD and NOK1.6 targe...

NANO NORDIC NANOVECTOR ASA
08/31/22 August 31, 2022 1 EN
Adam Karlsson ... (+2)
  • Adam Karlsson
  • Gonzalo Artiach
NANO Nordic Nanovect...

Nordic Nanovector - Q2 report

Company restructure leads to 70% staff reduction NOK ~185m in study closing costs leaves NOK ~100m Webcast today at 8:30 am CET

NANO NORDIC NANOVECTOR ASA
08/31/22 August 31, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch